‌

US Patent 10385130 Combination therapies of HDAC inhibitors and PD-1 inhibitors

Patent 10385130 was granted and assigned to HUYA Bioscience International on August, 2019 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

HUYA Bioscience International

0

Current Assignee

HUYA Bioscience International

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Alain Rolland0

Mireille Gillings0

Reid P. Bissonnette0

Date of Patent

August 20, 2019

0

Patent Application Number

155929880

Date Filed

May 11, 2017

0

Patent Citations

US Patent 10017492 Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof

Patent Citations Received

US Patent 12122833 Combination therapies of HDAC inhibitors and PD-1 inhibitors

0

US Patent 11535670 Combination therapies of HDAC inhibitors and PD-L1 inhibitors

Patent Primary Examiner

0

Patent abstract

Provided herein are combinations that include an HDACi and a PD-1 inhibitor that are useful for treating cancer, including reducing and/or preventing cancer metastasis. The combination is also useful for treating cancer that has been previously treated with a PD-L1 inhibitor.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10385130 Combination therapies of HDAC inhibitors and PD-1 inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool